Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme - Concepedia

Concepedia

Publication | Open Access

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme

DOI Full Paper Access

50

Citations

39

References

2019

Year

Stephen C. Bain, Brian Bekker Hansen, Samuel J. P. Malkin, Solomon Nuhoho, William J. Valentine, Barrie Chubb, Barnaby Hunt, Matthew Capehorn

Diabetes Therapy

Abstract

Oral semaglutide was cost-effective versus empagliflozin and sitagliptin, and dominant versus liraglutide, for the treatment of type 2 diabetes in the UK.

References

	Year	Citations

Page 1